Threshold Pharmaceuticals Announces Multiple Data Presentations on TH-302 at ... MarketWatch (press release) Together, the presentations will detail the results of studies combining TH-302, a hypoxia-targeted drug, with currently available therapies such as gemcitabine, Chk1 inhibitors and mTOR inhibitors in the treatment of various solid tumors and ... |
